Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Cid, Maria C; Unizony, Sebastian H; Blockmans, Daniel; Brouwer, Elisabeth; Dagna, Lorenzo; Dasgupta, Bhaskar; Hellmich, Bernhard; Molloy, Eamonn; Salvarani, Carlo; Trapnell, Bruce C; Warrington, Kenneth J; Wicks, Ian; Samant, Manoj; Zhou, Teresa; Pupim, Lara; Paolini, John F

Cid, Maria C; Unizony, Sebastian H; Blockmans, Daniel; Brouwer, Elisabeth; Dagna, Lorenzo; Dasgupta, Bhaskar; Hellmich, Bernhard; Molloy, Eamonn; Salvarani, Carlo; Trapnell, Bruce C; Warrington, Kenneth J; Wicks, Ian; Samant, Manoj; Zhou, Teresa; Pupim, Lara; Paolini, John F.

Afiliação

Cid MC; Department of Autoimmune Diseases, Hospital Clinic de Barcelona. University of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain MCCID@clinic.cat sunizony@mgh.harvard.edu.
Unizony SH; Vasculitis and Glomerulonephritis Center, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA MCCID@clinic.cat sunizony@mgh.harvard.edu.
Blockmans D; Clinical department of General Internal Medicine Department, Research Department of Microbiology and Immunology, Laboratory of Clinical Infectious and Inflammatory Disorders, Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
Brouwer E; Rheumatology and Clinical Immunology, Universitair Medisch Centrum Groningen afdeling Reumatologie & Klinische Immunologie, Groningen, The Netherlands.
Dagna L; Vita-Salute San Raffaele University, Milano, Italy.
Dasgupta B; Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milano, Italy.
Hellmich B; Rheumatology, Mid & South Essex University Hospitals NHS Foundation Trust, Southend University Hospital, Basildon, UK.
Molloy E; Klinik für Innere Medizin, Rheumatolgie und Immunologie, Medius KLINIKEN gemeinnutzige GmbH, Kirchheim unter Teck, Germany.
Salvarani C; Bone and Joint Unit, Saint Vincent's University Hospital, Dublin, Ireland.
Trapnell BC; Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Warrington KJ; Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplant, Oncology and Regenerative Medicine, Universita degli Studi di Modena e Reggio Emilia, Modena, Italy.
Wicks I; Translational Pulmonary Science Center, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.
Samant M; Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.
Zhou T; Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Pupim L; Rheumatology Unit, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Paolini JF; Kiniksa Pharmaceuticals Corp, Lexington, Massachusetts, USA.

Ann Rheum Dis ; 81(5): 653-661, 2022 05.

Article em En | MEDLINE | ID: mdl-35264321

Assuntos

Arterite de Células Gigantes; Anticorpos Monoclonais Humanizados/efeitos adversos; Método Duplo-Cego; Arterite de Células Gigantes/tratamento farmacológico; Glucocorticoides/uso terapêutico; Humanos; Prednisona/efeitos adversos; Resultado do Tratamento

Palavras-chave

giant cell arteritis; glucocorticoids; inflammation; systemic vasculitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Arterite de Células Gigantes Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google